Table 1. Subgroup analysis on objective response rate among cancer patients receiving anti-microtube agents to BRCA1 expression.
| Categories of included studies | Number of included studies | ORR (event/total) |
Test of heterogeneity |
Test of effect size |
Test for subgroup differences |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low/negative BRCA1 expression | High/positive BRCA1 expression | Chi2 | P value | I2 (%) | OR (95% CI) | P value | Chi2 | P value | I2 (%) | |||||
| Total | 9 | 90/342 | 140/380 | 20.32 | 0.01 | 61 | 1.63 (0.92, 2.88) | 0.09 | ||||||
| BRCA1 detection method | ||||||||||||||
| Immunohistochemical | 4 | 42/98 | 32/110 | 0.39 | 0.94 | 0 | 0.6 (0.33, 1.10) | 0.1 | 17.61 | <0.01 | 94 | |||
| Non-immunohistochemical | 5 | 48/244 | 108/270 | 1.92 | 0.75 | 0 | 2.90 (1.92, 4.39) | <0.01 | ||||||
| Therapeutic regimen | ||||||||||||||
| Platinum-based | 6 | 65/236 | 104/283 | 9.26 | 0.1 | 46 | 1.62 (1.10, 2.39) | 0.01 | 0.03 | 0.86 | 0 | |||
| Non platinum-based | 4 | 25/106 | 36/97 | 11.90 | 0.008 | 75 | 1.79 (0.41, 7.70) | 0.44 | ||||||
| Patient origin | ||||||||||||||
| Asia | 6 | 55/187 | 91/267 | 11.23 | 0.05 | 55 | 1.31 (0.65, 2.62) | 0.45 | 1.08 | 0.30 | 7.4 | |||
| Non-Asia area | 3 | 35/155 | 49/113 | 5.30 | 0.07 | 62 | 2.42 (0.95, 6.13) | 0.06 | ||||||
BRCA1, breast cancer susceptibility gene 1; ORR, objective response rate.